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Abstract
Objectives:  In  infants,  there  is  a  high  incidence  of  emergence  agitation  (EA)  after  sevoﬂurane
(Sev) anesthesia.  This  study  aimed  to  test  the  hypothesis  that  dexmedetomidine  (Dex)  admin-
istration would  reduce  the  incidence  and  severity  of  EA  after  Sev-based  anesthesia  in  infants
undergoing  palatoplasty.
Methods:  A  prospective  randomized  clinical  trial  was  conducted  with  70  patients  undergoing
palatoplasty,  aged  10--14  months.  Infants  were  randomly  allocated  into  two  groups:  Dex  (n  =  35)
and saline  (n  =  35).  In  the  Dex  group,  Dex  (6  g/kg/h)  was  administered  approximately  10  min
before the  end  of  the  surgery  for  10  min,  followed  by  0.4  g/kg/h  until  5  min  after  extubation.  In
the saline  group,  an  equivalent  amount  of  saline  was  administered  in  a  similar  manner.  After  the
surgery, patients  were  transferred  to  the  postanesthetic  care  unit  (PACU).  The  infant’s  behavior
and pain  were  assessed  with  scoring  system  for  EA  (5-point  rating  scale)  and  pain  scale  (PS;  10-
point rating  scale),  respectively.  EA  and  PS  were  estimated  at  six  time  points  (after  extubation,
leaving the  operating  room,  0,  30,  60,  and  120  min  after  arrival  in  PACU).
Results: EA  and  PS  scores  were  signiﬁcantly  lower  in  the  Dex  group  than  in  the  saline  group
from extubation  to  120  min  after  arrival  in  PACU.
Conclusions:  Dex  administration  has  the  advantage  of  a  reduced  EA  and  PS  without  any  adverse
effects. Dex  provided  satisfactory  recovery  in  infants  undergoing  palatoplasty.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.∗ Corresponding author.
E-mail: bokuaiji@dent.osaka-u.ac.jp (A. Boku).
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0104-0014/© 2015 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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Eﬁcácia  de  dexmedetomidina  para  o  surgimento  de  agitac¸ão em  lactentes  submetidos
à  palatoplastia:  estudo  clínico  randomizado
Resumo
Objetivos:  Em  crianc¸as,  é  elevada  a  incidência  de  surgimento  de  agitac¸ão  (SA)  em  seguida
à anestesia  com  sevoﬂurano  (Sev).  Este  estudo  teve  como  objetivo  testar  a  hipótese  de  que
a administrac¸ão  de  dexmedetomidina  (Dex)  reduziria  a  incidência  e  gravidade  do  SA  após
anestesia  com  Sev  em  lactentes  submetidos  à  palatoplastia.
Métodos:  Estudo  clínico  prospectivo  randomizado,  realizado  com  70  pacientes  submetidos  a
uma palatoplastia,  com  idades  entre  10-14  meses.  As  crianc¸as  foram  divididas  randomica-
mente em  dois  grupos:  Dex  (n  =  35)  e  soluc¸ão  salina  (n  =  35).  No  grupo  de  Dex,  Dex  (6  g/kg/h)
foi administrada  cerca  de  10  minutos  antes  do  ﬁnal  da  cirurgia  durante  10  min,  seguida  de
0,4 g/kg/h  até  5  minutos  após  a  extubac¸ão.  No  grupo  de  soluc¸ão  salina,  uma  quantidade
equivalente  de  salina  foi  administrada  com  o  mesmo  esquema  de  dosagem.  Após  a  cirurgia,  os
pacientes foram  transferidos  para  a  unidade  de  cuidados  pós-anestésicos  (UCPA).  O  compor-
tamento  e  a  dor  dos  bebês  foram  avaliados  com  um  sistema  de  pontuac¸ão  para  SA  (escala  de
classiﬁcac¸ão de  5  pontos)  e  com  uma  escala  de  dor  (ED;  escala  de  classiﬁcac¸ão  de  10  pontos),
respectivamente.  SA  e  ED  foram  estimados  em  seis  pontos  cronológicos  (após  a  extubac¸ão,  ao
deixar a  sala  de  cirurgia,  e  0,  30,  60  e  120  minutos  após  a  chegada  à  UCPA).
Resultados:  Os  escores  SA  e  ED  foram  signiﬁcativamente  menores  no  grupo  Dex  versus  grupo
salina, desde  a  extubac¸ão  até  120  min  após  a  chegada  à  UCPA.
Conclusões:  A  administrac¸ão  de  Dex  tem  a  vantagem  de  uma  reduc¸ão  no  SA  e  na  ED,  sem  quais-
quer efeitos  adversos.  Dex  proporcionou  uma  recuperac¸ão  satisfatória  em  lactentes  submetidos
à palatoplastia.
© 2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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evoﬂurane  (Sev)  is  a  popular  inhalational  anesthetic  in  chil-
ren.  It  is  characterized  by  a  more  rapid  onset  and  offset
ecause  of  a  lower  blood/gas  partition  coefﬁcient,  a  less
ungent  and  irritation  to  the  airway,  and  a  less  cardiode-
ressive  effect  when  compared  with  other  potent  inhaled
nesthetics.1,2 However,  the  incidence  of  emergence  agita-
ion  (EA)  after  Sev  anesthesia  is  high  in  infants,3,4 and  the
tiology  for  the  higher  incidence  of  EA  in  infants  is  unknown.
A  is  not  only  a  major  source  of  dissatisfaction  for  par-
nts  and  caregivers  postoperatively,  but  it  also  may  lead  to
ome  complications  such  as  increased  bleeding  from  opera-
ive  sites  and  pulling  out  an  intravenous  catheter.  Possible
tiological  factors  for  EA  include  a  rapid  recovery,  psycho-
ogical  immaturity,  otolaryngology  procedures,  anesthesia
ime,  and  concurrent  medications.5--8 Pediatric  anesthesi-
logists  should  consider  methods  to  reduce  the  risk  of  EA
fter  Sev  anesthesia.
In the  present  study,  we  focused  on  EA  in  speciﬁc  patients
ged  approximately  1  year  (10--14  months)  and  undergoing
alatoplasty  for  more  reliable  results  because  the  incidence
nd  severity  of  EA  depends  on  patient’s  age  and  procedure.9
tolaryngology  procedures  such  as  tonsillectomy  and  ade-
oidectomy  as  well  as  children  are  risk  factors  for  EA.10 A
ense  of  suffocation  in  airway  procedures  is  considered  a
ajor  cause  of  the  high  incidence  of  EA.
The  immediate  postoperative  period  after  palatoplasty
s  difﬁcult  because  this  surgery  has  speciﬁc  complications
t
s
gssociated  with  the  surgical  procedure.  Severe  pain  is
uspected  and  narrowing  of  the  upper  respiratory  tract
ay  result  in  transient  worsening  of  obstructive  symptoms
nd  hypoxemia.  Because  EA  after  palatoplasty  is  a  mild
omplication  in  comparison  with  lingual  swelling  and  other
irway-related  complications,11 rapid  emergence  from  anes-
hesia  may  be  desirable  to  allow  for  full  airway  control  after
xtubation.  Therefore,  it  is  important  that  prophylaxis  or
reatment  for  EA  after  palatoplasty  should  not  have  an  unfa-
orable  impact  on  airway.
Various  medications,  including  benzodiazepines,  keta-
ine,  and  propofol,  were  used  to  reduce  the  incidence  of
A.12 However,  there  is  no  well-established  prophylaxis  or
reatment  for  EA.  Although  supplemental  opioids  and/or
edatives  are  often  used  to  reduce  the  incidence  and
everity  of  EA,  anesthesiologists  should  always  consider  the
isk  of  postoperative  respiratory  complications.
Dexmedetomidine  (Dex),  a  potent  2-adrenoceptor
gonist,  has  sedative,  analgesic,  and  anxiolytic  proper-
ies  without  respiratory  depression.13 Some  studies  have
hown  the  effectiveness  of  Dex  in  postoperative  recov-
ry  in  a  pediatric  population  undergoing  tonsillectomy  and
denoidectomy.14,15 However,  the  effectiveness  of  Dex  in
ounger  infants  undergoing  palatoplasty  has  not  yet  been
ell  established.
The  objective  of  this  study  was  to  test  the  hypothesis  thathe  administration  of  Dex  would  reduce  the  incidence  and
everity  of  EA  after  Sev-based  anesthesia  in  infants  under-
oing  palatoplasty.
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Table  1  Scoring  system  for  emergence  agitation.
Score  Behavior
1  Sleeping
2  Awake,  Calm
3 Irritable,  crying
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Materials and methods
This  randomized  and  double-blind  study  was  approved  by
the  Institutional  Ethical  Committee  of  Osaka  University  Den-
tal  Hospital,  Suita,  Japan  (Chairperson  Prof.  S.  Wakisaka)  on
August  23,  2011  and  the  protocol  number  is  H23-E9.  Reg-
istration  for  this  study  (UMIN  000009869)  can  be  found  at
http://upload.umin.ac.jp.  Patient’s  parents  were  advised
about  the  risk  and  beneﬁts  of  participation  and  written
informed  consent  was  obtained.
Patients
Seventy  patients  undergoing  palatoplasty  were  enrolled  in
this  study.  Participants  were  required  to  be  ASA  physical
status  class  I,  aged  10--14  months  old,  weight  between
7  and  10  kg.  Exclusion  criteria  included  lack  of  consent,
ASA  class  >  II,  cardiovascular  disease,  or  a  history  of  air-
way  obstruction.  Randomization  was  performed  using  a
computer-generated  random  number  table.  Five  anesthesi-
ologists  participated  in  this  study,  and  each  had  over  7  years’
experience.  The  patient’s  parents  and  the  attending  anes-
thesiologist  were  blinded  to  the  group  allocation.  Patients
were  randomly  allocated  into  two  groups:  Dex  (n  =  35)  and
saline  (n  =  35).
Anesthesia  protocol
After  standard  monitoring  (including  pulse  oximetry,  elec-
trocardiogram,  noninvasive  arterial  blood  pressure)  in  the
operating  room,  anesthesia  was  induced  with  Sev  (4%).
After  induction,  endotracheal  intubation  was  facilitated
with  0.6  mg/kg  rocuronium.  Anesthesia  was  maintained  with
1%--2%  end-tidal  Sev  and  66%  nitrous  oxide  in  oxygen.  Fen-
tanyl  (20  g)  was  administered  as  a  bolus  to  patients  in
both  groups,  and  local  anesthetics  (1%  lidocaine  containing
adrenalin:  2  ml)  was  also  injected  into  the  operative  site.  In
the  Dex  group,  Dex  (6  g/kg/h)  was  continuously  adminis-
tered  approximately  10  min  before  the  end  of  the  surgery  for
10  min,  followed  by  0.4  g/kg/h  until  5  min  after  the  extu-
bation.  In  the  saline  group,  an  equivalent  amount  of  saline
was  administered  in  a  similar  manner.  At  the  end  of  the
surgery,  anesthetic  gases  were  discontinued.  The  trachea
was  extubated  when  patients  were  awake.  Patients  were
then  transferred  to  the  postanesthetic  care  unit  (PACU),
and  both  groups  received  rectal  acetaminophen  (200  mg).
In  PACU,  parents  were  allowed  to  be  with  their  child.  Sup-
plemental  oxygen  was  administered  when  SpO2 decreased
to  less  than  95%.
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Table  2  Scoring  system  for  pain  scale.
Category  Score  0  Score  1  
Face  No  particular  expression  or  smile  Occasional  gr
Legs Normal  position  Uneasy,  restl
Activity Lying  quietly,  moves  easily  Squirming,  sh
Cry No  crying  Moans  or  whi
Consolability  Content,  relaxed  Reassured  by
Each scale was added and expressed as a total points.4 Inconsolable  crying
5 Severe  restlessness,  disorientation
We  evaluated  time  to  extubation  (TE),  which  was  deﬁned
s  the  time  from  discontinuation  of  Sev  and  nitrous  oxide  to
xtubation.  Heart  rate  (HR),  mean  arterial  blood  pressure
MAP),  and  SpO2 were  documented  before,  undergoing,  and
fter  the  administration  of  Dex  or  saline.  To  assess  the  EA
nd  pain  scale  (PS)  score,  the  scoring  system  for  EA  and
S  score  were  used.  EA  was  assessed  with  a  5-point  scale
Table  1).5 PS  score  was  assessed  by  Face,  Legs,  Activity,  Cry,
onsolability  (FLACC)  Scale  (Table  2).16 This  pain  assessment
cale  was  used  for  nonverbal  patients.  Each  scale  has  three
ategories.  We  added  each  scale  and  expressed  it  as  total
oints.  EA  and  PS  score  were  estimated  at  six  time  points
after  extubation,  leaving  the  operating  room,  0,  30,  60,  and
20  min  after  arrival  in  PACU).  Data  for  each  patient  were
btained  by  the  blinded  anesthesiologist.
tatistical  analysis
efore  initiating  the  study,  a  power  analysis  suggested  that
 sample  size  of  35  patients  in  each  groups  are  required
o  show  that  the  administration  of  Dex  would  decrease  the
ncidence  of  severe  EA  (point  4  or  5)  after  the  surgery  by
0%  with  80%  power  (˛  =  0.05)  in  comparison  with  the  control
roup.
Data  are  presented  as  number  (n),  mean  (SD),  or  median
IQR)  as  appropriate.  Student’s  t-test  was  used  for  height,
eight,  age,  anesthesia  time,  surgery  time,  and  TE.  Chi-
quare  for  independence  test  2  ×  2  contingency  table  was
sed  for  sex.  Two-factor  repeated-measures  ANOVA  and
ultiple  comparison  was  used  for  HR  and  MAP.  EA  and  PS
core  were  compared  between  groups  with  Mann--Whitney’s
-test.  p-values  of  <0.05  were  considered  statistically  sig-
iﬁcant.
esultsighty  infants  presenting  with  palatoplasty  under  general
nesthesia  were  assessed  for  eligibility  from  August  2011  to
uly  2012.  Fig.  1  shows  the  CONSORT  ﬂow  chart  detailing
Score  2
imace  Frequent  to  constant  frown
ess  Kicking  or  legs  drawn  up
ifting  back  Arched  rigid
mpers  Crying  steadily,  screams
 occasional  touching,  hugging  Difﬁcult  to  console
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Enrollment
Assessed for eligibility (n=80)
Randomized (n=70)
Excluded (n=10)
Not meeting inclusion criteria (n=2)
Declined to participate (n=8)
Allocated to intervention (n=35)
Received allocated intervention (n=35)
Did not receive allocated intervention 
(give reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) 
(n=0)
Analysed (n=35)
Excluded from analysis (give reasons) (n=0)
Analysed (n=35)
Excluded from analysis (give reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) 
(n=0)
Did not receive allocated intervention 
(give reasons) (n=0)
Allocated to intervention (n=35)
Received allocated intervention (n=35)
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(Figure  1  Consolidated  Standards  of  Reporting  Trials  (C
atient  recruitment.  Data  analysis  was  performed  on  two
roups  (Dex  group,  n  =  35;  saline  group,  n  =  35).
Details  of  demographic  characteristics  are  summarized  in
able  3.  There  were  no  differences  between  the  two  groups
n  patient  demographics,  surgery  time,  and  anesthesia  time.
otal  dosage  of  Dex  was  11.5  (2.5)  g.  TE  was  signiﬁcantly
onger  in  the  Dex  group  [8.1  (2.9)  min]  than  in  the  saline
roup  [6.4  (1.9)  min].  Tables  4  and  5  demonstrated  the  sco-
ing  system  for  EA  and  PS  score.  EA  and  PS  scores  were
igniﬁcantly  lower  in  the  Dex  group  than  in  the  saline  group
uring  the  observation  period.
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Table  3  Demographic  data.
Dex  (n  =  35)  
Patient  characteristics
Age  (month)  12.2  (1.5)  
Male/Female 14/22  
Height (cm)  74.9  (3.1)  
Weight (kg)  8.8  (1.0)  
Surgery characteristics
Surgery  time  (min)  76.5  (22.2)  
Anesthesia time  (min)  148.5  (19.8)  
TE (min)a 8.1  (2.9)  
Total amount  of  Dex  (g)  11.5  (2.5)
Data are expressed by mean (SD); NS, not signiﬁcant.
a p < 0.05; Dex vs. saline.ORT)  recommended  description  of  patient  recruitment.
Two  patients  in  each  group  required  supplemental  oxy-
en  because  of  reduced  SpO2 (Table  6);  however,  none  of
hese  patients  exhibited  any  signs  of  airway  obstruction  and
rolonged  oxygen  requirement.
MAP  and  HR  after  extubation  (after  administration  of
ex)  were  signiﬁcantly  lower  in  the  Dex  group  [59.7
5.3)  mmHg,  128.1  (9.8)  beats/min,  respectively]  than  in
he  saline  group  [67.3  (6.6)  mmHg,  142.5  (9.7)  beats/min,
espectively].  Hemodynamic  instability  did  not  occur  in  any
f  the  patients,  and  vital  signs  remained  within  20%  of  base-
ine  in  all  patients  (Figs.  2  and  3).
Saline  (n  =  35)  p  value
11.9  (1.6)  0.44  NS
16/19  0.21  NS
74.0  (3.8)  0.23  NS
8.9  (1.2)  0.32  NS
74.5  (15.1)  0.18  NS
143.0  (25.0)  0.39  NS
6.4  (1.9)  0.01
Effectiveness  of  dexmedetomidine  for  emergence  agitation  in  infants  41
Table  4  The  scoring  system  for  emergence  agitation  at  six  points  of  time.
After  extubation  Leaving  the  operating  room  Time  from  arrival  in  the  postanesthetic  care  unit  (min)
0  30  60  120
Saline
3  3  3  3  3  2
(3--4) (3--4)  (3--3.5)  (3--3)  (2--3)  (1--3)
Dex
3a 1a 1a 1.5a 1a 1a
(2--3) (1--2) (1--2) (1--2)  (1--2)  (1--2)
Data are expressed as median (IQR).
a p < 0.05; Dex vs. saline.
Table  5  The  scoring  system  for  pain  scale  at  six  points  of  time.
After  extubation  Leaving  the  operating  room  Time  from  arrival  in  the  postanesthetic  care  unit  (min)
0  30  60  120
Saline
9  8  8  6  5  5
(8--9) (7--9)  (6--9)  (5--8)  (3.5--6)  (3.5--6)
Dex
7a 1a 1.5a 2a 1a 0a
(2.75--9)  (0--4.25)  (0--4)  (0--3.25)  (0--2.25)  (0--2)
Data are expressed as median (IQR).
a p < 0.05; Dex vs. saline.
Table  6  Desaturation  episode  with  SpO2 below  95%  after
extubation.
after  Sev  anesthesia  in  infants  undergoing  palatoplasty.  The
effects  on  EA  and  PS  score  lasted  for  more  than  2  h  after  the
surgery.
Dex  is  a  potent  2-adrenoceptor  agonist  and  primar-
ily  used  as  a postoperative  sedative  in  ICU.17 Recently,
Dex  is  increasingly  used  for  procedural  sedation  during
awake  ﬁberoptic  intubation,18 colonoscopy,19 and  magnetic
resonance  imaging  (MRI)  for  young  children.20--22 Dex  isSaline  2/35
Dexmedetomidine  2/36
DiscussionThe  results  of  this  study  show  that  Dex  has  the  advantage
of  a  reduced  EA  and  PS  score  without  any  adverse  effects
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Figure  2  Mean  arterial  blood  pressure  (MAP)  responses  at  the
time of  before,  undergoing,  after  administration  of  dexmedeto-
midine  (Dex)  or  saline.  Data  are  mean  (SD).  *p  <  0.05  versus
before  administration.
also  extremely  useful  as  a  sedative  for  children  under-
going  tonsillectomy  and  adenoidectomy.10 These  reports
suggest  a  possible  beneﬁcial  effect  of  Dex  for  postoperative
management  after  palatoplasty.  The  present  study  clearly
HR
Before
administration
Under
administration
After
administration
Dex Saline
0
40
80
120
160
H
R
 b
ea
ts
/m
in
Figure  3  Heart  rate  (HR)  responses  at  the  time  of  before,
undergoing,  and  after  administration  of  dexmedetomidine  (Dex)
or saline.  Data  are  mean  (SD).  *p  <  0.05  versus  before  adminis-
tration.
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emonstrated  the  effectiveness  of  Dex  on  the  reduction  in
A  score.
Pain  is  a  major  factor  increasing  the  severity  and  fre-
uency  of  agitation,  and  sufﬁcient  analgesia  leads  to  the
eduction  in  agitation.23,24 Dex  is  beneﬁcial  for  pain  treat-
ent.  Dex  demonstrates  peripheral  and  centrally  mediated
ntinociception  via  receptor  activation  in  the  dorsal  horn
nd  the  locus  coeruleus.25,26 Dex  administered  before  the
nd  of  surgery  reduced  morphine  requirement  in  the  imme-
iate  postoperative  period  in  adult  patients  undergoing
ajor  abdominal  or  orthopedic  procedures.27 Patel  et  al.14
lso  reported  that  an  intraoperative  infusion  of  Dex  sig-
iﬁcantly  reduced  the  postoperative  opioid  requirement  in
hildren.  Our  PS  score  results  indicate  that  Dex  provides
onsiderable  analgesia  following  palatoplasty.
Some  studies  have  demonstrated  that  opioids  are  effec-
ive  to  relieve  EA  after  Sev  anesthesia.28 However,  in  the
ostoperative  period  following  palatoplasty,  effective  anal-
esia  with  opioid  alone  would  be  difﬁcult  to  provide  without
ny  effects  on  airway.  In  contrast,  there  are  evidences  that
ven  pain-free  children  with  caudal  block  or  undergoing  MRI
ecome  agitated  during  emergence  from  anesthesia.29,30 EA
ften  occurs  even  after  adequate  pain  treatment  or  after
rocedures  that  are  not  associated  with  pain.  Because  Dex
as  both  sedative  and  analgesic  properties,  it  is  beneﬁcial
ven  in  such  situations.
Dex  can  lead  to  dose-dependent  bradycardia,  hypo-  or
ypertension  in  children,  when  Dex  is  applied  as  a  sole
gent  for  sedation.31,32 Bloor  et  al.33 reported  that  after
he  administration  of  Dex,  there  is  a  decrease  in  the  HR
nd  biphasic  blood  pressure  response  with  a  short  ini-
ial  increase,  followed  by  a  prolonged  decrease  of  the
lood  pressure.  The  decrease  in  blood  pressure  and  HR  are
he  result  of  the  stimulation  of  central  presynaptic  2a-
drenergic  receptor.31,33
In  this  study,  Dex  was  administered  at  an  intraoperative
nitial  loading  dose  of  6  g/kg/h,  followed  by  an  infusion
t  0.4  g/kg/h.  HR  and  MAP  after  extubation  were  signiﬁ-
antly  lower  in  the  Dex  group  than  in  the  saline  group,  but  no
erious  circulatory  depression  was  observed  after  the  admin-
stration  of  Dex.  A  recent  meta-analysis  revealed  a  lower
isk  for  EA  following  Dex  in  comparison  with  placebo.34 How-
ver,  there  were  large  differences  in  Dex  regimen  (low  dose:
.15  g/kg,  high  dose:  4  g/kg)  between  studies.  Shurky
t  al.35 also  reported  that  Dex  was  used  successfully  as  a
ontinuous  infusion  (0.2  g/kg/h)  for  15  min  in  the  postop-
rative  period  to  prevent  or  reduce  EA  in  children.  On  the
ther  hand,  Guler  et  al.10 and  Ibacache  et  al.36 reported
hat  a  single  dose  of  Dex  (0.5  g/kg)  5  min  before  the  end  of
urgery  and  0.3  g/kg  after  induction  of  anesthesia  reduced
A  without  signiﬁcant  hemodynamic  effects,  respectively.
hus,  the  administration  of  Dex  at  a  slow  rate  may  con-
ribute  to  hemodynamic  stability.
In  our  study,  two  patients  in  each  group  required  supple-
ental  oxygen  because  of  reduced  SpO2 after  extubation;
owever,  none  of  these  patients  exhibited  signs  of  airway
bstruction  and  prolonged  oxygen  requirement.
There  are  some  limitations  in  our  study.  First,  although
ain  is  deﬁnitely  a  major  reason  for  EA,  screaming  as  a
esult  of  pain  should  be  distinguished  from  EA.  However,
t  is  impossible  to  distinguish  between  them  in  children  in
he  preverbal  stage  of  development.  Furthermore,  there  areA.  Boku  et  al.
ome  difﬁculties  in  interpreting  behavior  with  other  inﬂu-
ncing  factors  such  as  hunger  or  fear  of  strangers.  Although
t  is  uncertain  whether  postoperative  rectal  acetaminophen
rovided  the  expected  level  of  analgesia,  the  analgesic  and
edative  effects  of  Dex  would  to  be  advantageous  to  this
ituation  in  infants.
Second,  we  used  the  scoring  system  for  EA  and  PS
core.5,16 Five  anesthesiologists  participated  to  assess  EA
nd  PS  score  in  our  study.  Although  the  method  we  used
s  well  accepted  and  has  been  validated  in  other  studies,5,30
here  may  be  a  difference  in  an  evaluation  of  EA  and  PS  score
ue  to  experimenter’s  bias.  If  we  use  another  criterion,  dif-
erent  results  may  be  obtained.
Third,  it  is  important  to  note  that  we  studied  relatively
ealthy  infants  and  excluded  infants  with  a  history  of  air-
ay  problems  because  Dex  required  in  the  study  protocol
ay  subject  these  infants  to  unacceptably  greater  risks  for
ostoperative  airway  complications.  In  the  absence  of  such
 study,  we  would  urge  caution  in  the  use  of  Dex  in  infants
ith  documented  airway  obstruction.  Further  studies  focus-
ng  on  obstructive  airway  complications  due  to  Dex  in  infants
ith  Robin  sequence  and/or  Treacher  Collins  syndrome  are
eeded.
In  conclusion,  although  our  sample  size  is  small,  it  seems
hat  the  use  of  Dex  reduced  EA  and  PS  score  without  any
dverse  effects  and  provided  satisfactory  recovery  with  sta-
le  hemodynamics  in  infants  undergoing  palatoplasty.
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